Ceapro Inc V.CZO

CZO is in play

[boazklinghorn]

Happy 2024 lets hope it is better than 2023. Gilles has put CZO in play. He did it for his own selfish reasons but he has now done it. THe process completley ignored shareholder interests but it is now done. It is our job now to get a competing offer. Anyone who still has an actual live broker make sure to tell them, anyone who is actually in the business tell your collegues and bosses. I have rreached out to several companies already. To my mind the ideal buyer is around 100 miilion market cap and profiable with a compatible business in the health wellness sector. Willing to do an all share deal that would give us 40ish percent of the newco, Most importantly we need young agressive engaged mangers to finally get us the growth we have all been waiting years for. Ceapro at 15 million market cap and 8 or 9 million cash is ripe for the plucking so lets find a good buyer and beat Gilles and Ronnie at their own game.

[Tencents]

You probably have about 2 years to make a deal - at that point  cash will run out  aezs run significant losses - it's possible the growth hormone test device may not make any roads into markets and at best would deliver small revenues anyway CZo seem to have lost their base business and don't have any pipeline products coming through this decade 

[Ciao]

Most companies would have announced the reason for and the special committee, but since these companies are far from being shareholder friendly, and it's a sham result with a non arms length deal, likely known from the onset, they decided to keep Ceapro investors in the dark... https://www.mondaq.com/canada/corporate-governance/60842/20-questions-directors-should-ask-about-special-committees

[lscfa]

if merger fails Gagnon will have blown another $2.5M on legal costs. For the 9 months ended Sept 30/23 legal expenses were $1.5M

[prophetoffactz]

Numerous costs may be ramping up. - Avenanthramide clinical trial enrollment, dosing, monitoring in a hospital for three days. - Simultaneous PGX scale-up to 50L and 100L including with Natex. - Angiogenesis Foundation study is ongoing according to a press release. - "Protocol designed for a head-to-head study in animals for testing immune properties of PGX-YBG against a commercial

[Ciao]

They have enough funds to execute, if Gilles can't or doesn't want to do it as shown by his eagerness to sell CZO below liquidation value, he needs to be shown the door... “While the base business has been significantly impacted during the first nine months of 2023 due to various economic factors and organizational changes in one major customer, we remain in a solid financial position and